TY - JOUR
T1 - Therapeutic potential of stem cells for preterm infant brain damage
T2 - Can we move from the heterogeneity of preclinical and clinical studies to established therapeutics?
AU - Passera, Sofia
AU - Boccazzi, Marta
AU - Bokobza, Cindy
AU - Faivre, Valerie
AU - Mosca, Fabio
AU - Van Steenwinckel, Juliette
AU - Fumagalli, Monica
AU - Gressens, Pierre
AU - Fleiss, Bobbi
N1 - Funding Information:
The authors? research is supported by the Inserm, Universit? Paris Diderot, Cerebral Palsy Alliance Australia, ?Investissement d'Avenir -ANR-11- INBS-0011-?NeurATRIS, Fondation Grace de Monaco, Fondation Roger de Spoelberch, PremUP, Fondation des Gueules Cass?es the European Union's Horizon 2020 research and innovation programme under grant agreement No 874721 and the National Health and Medical Research Council (Australia). Thumbnail image for publication created with BioRender.com.
Funding Information:
The authors’ research is supported by the Inserm, Université Paris Diderot, Cerebral Palsy Alliance Australia, “Investissement d’Avenir -ANR-11- INBS-0011-“NeurATRIS, Fondation Grace de Monaco, Fondation Roger de Spoelberch, PremUP, Fondation des Gueules Cassées the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874721 and the National Health and Medical Research Council (Australia). Thumbnail image for publication created with BioRender.com.
Publisher Copyright:
© 2021 Elsevier Inc.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Acquired perinatal brain injuries are a set of conditions that remains a key challenge for neonatologists and that have significant social, emotional and financial implications for our communities. In our perspective article, we will introduce perinatal brain injury focusing specifically on the events leading to brain damage in preterm born infants and outcomes for these infants. Then we will summarize and discuss the preclinical and clinical studies testing the efficacy of stem cells as neuroprotectants in the last ten years in perinatal brain injury. There are no therapies to treat brain damage in preterm born infants and a primary finding from this review is that there is a scarcity of stem cell trials focused on overcoming brain injuries in these infants. Overall, across all forms of perinatal brain injury there is a remarkable heterogeneity in previous and on-going preclinical and clinical studies in terms of the stem cell type, animal models/patient selection, route and time of administration. Despite the quality of many of the studies this variation makes it difficult to reach a valid consensus for future developments. However, it is clear that stem cells (and stem cell derived exosomes) can reduce perinatal brain injury and our field needs to work collectively to refine an effective protocol for each type of injury. The use of standardized stem cell products and testing these products across multiple models of injury will provide a stronger framework for clinical trials development.
AB - Acquired perinatal brain injuries are a set of conditions that remains a key challenge for neonatologists and that have significant social, emotional and financial implications for our communities. In our perspective article, we will introduce perinatal brain injury focusing specifically on the events leading to brain damage in preterm born infants and outcomes for these infants. Then we will summarize and discuss the preclinical and clinical studies testing the efficacy of stem cells as neuroprotectants in the last ten years in perinatal brain injury. There are no therapies to treat brain damage in preterm born infants and a primary finding from this review is that there is a scarcity of stem cell trials focused on overcoming brain injuries in these infants. Overall, across all forms of perinatal brain injury there is a remarkable heterogeneity in previous and on-going preclinical and clinical studies in terms of the stem cell type, animal models/patient selection, route and time of administration. Despite the quality of many of the studies this variation makes it difficult to reach a valid consensus for future developments. However, it is clear that stem cells (and stem cell derived exosomes) can reduce perinatal brain injury and our field needs to work collectively to refine an effective protocol for each type of injury. The use of standardized stem cell products and testing these products across multiple models of injury will provide a stronger framework for clinical trials development.
KW - Encephalopathy of prematurity
KW - Exosomes
KW - Perinatal brain injury
UR - http://www.scopus.com/inward/record.url?scp=85101148539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101148539&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2021.114461
DO - 10.1016/j.bcp.2021.114461
M3 - Review article
C2 - 33571501
AN - SCOPUS:85101148539
VL - 186
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
SN - 0006-2952
M1 - 114461
ER -